The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …

Lung cancer remains the leading cause of malignancy-related deaths in the USA,
regardless of advances in therapeutic agents. Non-small-cell lung cancer demonstrates …

Simple Summary The use of novel therapeutic drugs in lung cancer has changed the
paradigm of the diagnosis and treatment of lung cancer. Due to the development of …

Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

Conventional treatment of non-small-cell lung cancer (NSCLC) has apparently reached a
plateau of effectiveness in improving the survival of NSCLC patients. Although neoadjuvant …

Non-small-cell lung cancer (NSCLC) is a major global health problem and is the leading
cause of cancer death worldwide. Current treatment involves nonspecific, nonselective …

Simple Summary The discovery of actionable oncogenic driver mutations in non-small-cell
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …

Lung cancer is a highly heterogeneous disease often driven by well-characterized driver
mutations. Although the best studied are common alterations in the epidermal growth factor …

The last decade has witnessed the development of oncogene-directed targeted therapies
that have significantly changed the treatment of non-small-cell lung cancer (NSCLC). In this …

Advances in the treatment of non-small cell lung cancer (NSCLC) over the last decade have
predominantly involved the development of therapies directed at molecular targets such as …